| Autor: |
Weijia Li, Saul Rios, Sanjana Nagraj, Adrija Hajra, Tinatin Saralidze, Dimitrios Varrias, Sheetal Vasundara Mathai, Marko Novakovic, Kenneth H. Hupart, Jeremy A. Miles, Adarsh Katamreddy, Leonidas Palaiodimos, Robert T. Faillace |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
The American journal of medicine. 135(7) |
| ISSN: |
1555-7162 |
| Popis: |
Statins have been commonly used for primary and secondary cardiovascular prevention. We hypothesized that statins may improve in-hospital outcomes for hospitalized patients with Coronavirus disease 2019 (COVID-19) due to its known anti-inflammatory effects.We conducted a retrospective study at the largest municipal health care system in the United States, including adult patients who were hospitalized for COVID-19 between March 1 and December 1, 2020. The primary endpoint was in-hospital death. Propensity score matching was conducted to balance possible confounding variables between patients receiving statins during hospitalization (statin group) and those not receiving statins (non-statin group). Multivariate logistic regression was used to evaluate the association of statin use and other variables with in-hospital outcomes.There were 8897 patients eligible for study enrollment, with 3359 patients in the statin group and 5538 patients in the non-statin group. After propensity score matching, both the statin and non-statin groups included 2817 patients. Multivariate logistic regression analysis showed that the statin group had a significantly lower risk of in-hospital mortality (odds ratio 0.71; 95% confidence interval, 0.63-0.80; P.001) and mechanical ventilation (OR 0.80; 95% confidence interval, 0.71-0.90; P.001) compared with the non-statin group.Statin use was associated with lower likelihood of in-hospital mortality and invasive mechanical ventilation in hospitalized patients with COVID-19. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
